With its cancer products portfolio nearing a launch, DARA BioSciences (NASDAQ:DARA) is making the adjustments necessary to transition to become a revenue-producing company. DARA earlier this month closed on a stock sale that raised just over $10 million to support commercialization of its cancer products. Now the company is making some management moves to prepare […]
The cancer products portfolio that DARA BioSciences (NASDAQ:DARA) has been building by acquisition now has more than $9 million in fresh capital to help bring those products to market. The pharmaceutical company has completed a securities offering of preferred stock and warrants, according to securities filings. Raleigh, North Carolina-based DARA sold 10,250 shares of preferred […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The cancer treatment portfolio of DARA BioSciences (NASDAQ:DARA) has added its third cancer product in as many months, a topical product to treat radiation and chemotherapy burns. DARA said that it has entered into an exclusive agreement with Charleston, South Carolina-based Innocutis Holdings for the U.S. rights of Bionect, a product that comes as […]
The cancer treatment portfolio of DARA BioSciences (NASDAQ:DARA) is getting bigger as the pharmaceutical company strikes a deal to market the generic version of a drug used as a first-in-line treatment for several cancers. DARA’s deal with Canadian specialty pharmaceutical company Uman Pharma gives DARA exclusive rights to commercialize gemcitabine in the United States. But […]
DARA BioSciences (NASDAQ:DARA), which earlier this week acquired cancer therapeutics firm Oncogenerix, has made yet another deal, this one an agreement to raise $1.7 million in a private placement. DARA has reached a definitive agreement with an unnamed institutional investor to sell preferred stock valued at $1.7 million and warrants to purchase 619,308 shares of […]
Breast cancer treatment Soltamox — a liquid version of Tamoxifen — now belongs to DARA BioSciences (NASDAQ:DARA) as the clinical-stage pharmaceutical company acquires the product in a move that positions the company to sell and develop products for the lucrative cancer drug market. The U.S. rights to Soltamax come to DARA via the acquisition of […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
North Carolina biotechnology company DARA BioSciences (NASDAQ:DARA) has named Dr. David Drutz the company’s new CEO. Drutz had been named interim CEO of the Raleigh company earlier this month following the retirement of former Chairman and CEO Richard Franco. On Dec. 19, DARA’s board of directors approved the removal of “interim” from Drutz’s title, making […]
DARA BioSciences (NASDAQ:DARA) is looking for a new CEO. Current CEO Richard Franco will retire from his posts as chairman, president and CEO of the Raleigh, North Carolina biotechnology company effective Dec. 16. DARA said that Dr. David Drutz, a member of the company’s board of directors, will serve as interim CEO. Franco notified the […]
Drug development company DARA BioSciences (NASDAQ:DARA) could lose its listing on the NASDAQ exchange today. DARA received notification from the NASDAQ that based on its last quarterly report, the Raleigh, North Carolina company no longer maintained the minimum $2.5 million in stockholders’ equity required for a listing. DARA said in a securities filing that the […]
North Carolina biotechnology company DARA BioSciences (NASDAQ:DARA) has strengthened its intellectual position by securing five new patents for its drug pipeline. DARA said the five new patents were granted in the United States, Asia and Israel. The Raleigh, North Carolina company has two drug candidates in clinical trials. KRN5500 is in development as a treatment […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
DARA BioSciences‘s (NASDAQ:DARA) investigational pain treatment for cancer patients now has fast-track status from the U.S. Food and Drug Administration. The compound KRN5500 is being developed with the National Cancer Institute to treat neuropathic pain brought on by chemotherapy. The FDA’s fast-track program is intended to facilitate development and speed regulatory review of new drugs […]
Intellectual property protection for DARA BioSciences‘s drug pipeline just got a little more secure. Raleigh, North Carolina-based DARA (NASDAQ:DARA) has been issued nine patents in the United States and around the world, which gives it additional intellectual property protection for compounds being developed as new treatments for diabetes, obesity, cardiovascular disease and pain. DARA does […]
Drug development company DARA BioSciences is updating its plans to raise up to $30 million through a stock sale. Raleigh, North Carolina-based DARA (NASDAQ:DARA) has filed a new shelf registration statement with the U.S. Securities and Exchange Commission, which replaces a filing set to expire on April 18. DARA said it has no plans to […]
Dara, based in Raleigh, North Carolina, wanted to raise $4 million through a registered public. The company wound up raising $4.8 million. Proceeds will total about $4.3 million.